Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis

Robert J. Bauer(XOMA (United States)), Russell L. Dedrick(XOMA (United States)), Mark White(XOMA (United States)), Michael J. Murray(XOMA (United States)), Marvin R. Garovoy(XOMA (United States))

Journal of Pharmacokinetics and Biopharmaceutics

August 1, 1999

10.1023/a:1020917122093

Cited by 135

Abstract

Related Papers

CTLA-4 is a second receptor for the B cell activation antigen B7.

Peter S. Linsley, William Brady, M Urnes et al.|The Journal of Experimental Medicine|1991|1.7k

Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells.

Michael L. Dustin, Timothy A. Springer|The Journal of Cell Biology|1988|990

Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule

Peter S. Linsley, Philip M. Wallace, Jennifer Johnson et al.|Science|1992|806

Metabolism of Immunoglobulins

Thomas A. Waldmann, Warren Strober|Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy|2015|726

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

Scott Gottlieb, Patricia Gilleaudeau, Ray A. Johnson et al.|Nature Medicine|1995|614